Functional Neuromodulation, Ltd. Initiates North American Study of Deep Brain Stimulation for Alzheimer’s Disease
8/7/2012 10:08:45 AM
TORONTO--(BUSINESS WIRE)--Functional Neuromodulation Ltd has initiated the ADvance Study in the U.S. and Canada to assess deep brain stimulation (DBS) in patients with mild Alzheimer’s disease. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain’s memory circuit. Research suggests this is an area affected early in the development of Alzheimer’s. The first ADvance patient enrolled has been successfully implanted.